CLINICAL EFFICACY OF LEFLUNOMIDE/HYDROXYCHLOROQUINE COMBINATION THERAPY IN PRIMARY SJOGREN'S SYNDROME IS PREDICTED BY SERUM PROTEOME BIOMARKERS - RESULTS FROM REPURPSS-I

Joel Van Roon; Eefje van der Heijden; Sofie Blokland; Ana Lopes; Frederique Moret; Paco Welsing; Nard Janssen; Toine Rosenberg; Aridaman Pandit; Weiyang Tao; Maarten Hillen; Aike A. Kruize; Timothy R. Radstake

doi:10.1136/annrheumdis-2019-eular.5681

CLINICAL EFFICACY OF LEFLUNOMIDE/HYDROXYCHLOROQUINE COMBINATION THERAPY IN PRIMARY SJOGREN'S SYNDROME IS PREDICTED BY SERUM PROTEOME BIOMARKERS - RESULTS FROM REPURPSS-I

Joel Van Roon
, Eefje van der Heijden
, Sofie Blokland
, Ana Lopes
, Frederique Moret
, Paco Welsing
, Nard Janssen
, Toine Rosenberg
, Aridaman Pandit
, Weiyang Tao
, Maarten Hillen
, Aike A. Kruize
, Timothy R. Radstake

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	396-396
Number of pages	1
Journal	Annals of the Rheumatic Diseases
Volume	78
Issue number	Suppl 2
DOIs	https://doi.org/10.1136/annrheumdis-2019-eular.5681
Publication status	Published - Jun 2019

Access to Document

10.1136/annrheumdis-2019-eular.5681

Cite this

Van Roon, J., van der Heijden, E., Blokland, S., Lopes, A., Moret, F., Welsing, P., Janssen, N., Rosenberg, T., Pandit, A., Tao, W., Hillen, M., Kruize, A. A., & Radstake, T. R. (2019). CLINICAL EFFICACY OF LEFLUNOMIDE/HYDROXYCHLOROQUINE COMBINATION THERAPY IN PRIMARY SJOGREN'S SYNDROME IS PREDICTED BY SERUM PROTEOME BIOMARKERS - RESULTS FROM REPURPSS-I. Annals of the Rheumatic Diseases, 78(Suppl 2), 396-396. https://doi.org/10.1136/annrheumdis-2019-eular.5681

@article{86c4d54da0e144259b90c907d84c5f7a,

title = "CLINICAL EFFICACY OF LEFLUNOMIDE/HYDROXYCHLOROQUINE COMBINATION THERAPY IN PRIMARY SJOGREN'S SYNDROME IS PREDICTED BY SERUM PROTEOME BIOMARKERS - RESULTS FROM REPURPSS-I",

author = "\{Van Roon\}, Joel and \{van der Heijden\}, Eefje and Sofie Blokland and Ana Lopes and Frederique Moret and Paco Welsing and Nard Janssen and Toine Rosenberg and Aridaman Pandit and Weiyang Tao and Maarten Hillen and Kruize, \{Aike A.\} and Radstake, \{Timothy R.\}",

year = "2019",

month = jun,

doi = "10.1136/annrheumdis-2019-eular.5681",

language = "English",

volume = "78",

pages = "396--396",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier",

number = "Suppl 2",

}

Van Roon, J, van der Heijden, E, Blokland, S, Lopes, A, Moret, F, Welsing, P, Janssen, N, Rosenberg, T, Pandit, A, Tao, W, Hillen, M, Kruize, AA & Radstake, TR 2019, 'CLINICAL EFFICACY OF LEFLUNOMIDE/HYDROXYCHLOROQUINE COMBINATION THERAPY IN PRIMARY SJOGREN'S SYNDROME IS PREDICTED BY SERUM PROTEOME BIOMARKERS - RESULTS FROM REPURPSS-I', Annals of the Rheumatic Diseases, vol. 78, no. Suppl 2, pp. 396-396. https://doi.org/10.1136/annrheumdis-2019-eular.5681

CLINICAL EFFICACY OF LEFLUNOMIDE/HYDROXYCHLOROQUINE COMBINATION THERAPY IN PRIMARY SJOGREN'S SYNDROME IS PREDICTED BY SERUM PROTEOME BIOMARKERS - RESULTS FROM REPURPSS-I. / Van Roon, Joel; van der Heijden, Eefje; Blokland, Sofie et al.
In: Annals of the Rheumatic Diseases, Vol. 78, No. Suppl 2, 06.2019, p. 396-396.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - CLINICAL EFFICACY OF LEFLUNOMIDE/HYDROXYCHLOROQUINE COMBINATION THERAPY IN PRIMARY SJOGREN'S SYNDROME IS PREDICTED BY SERUM PROTEOME BIOMARKERS - RESULTS FROM REPURPSS-I

AU - Van Roon, Joel

AU - van der Heijden, Eefje

AU - Blokland, Sofie

AU - Lopes, Ana

AU - Moret, Frederique

AU - Welsing, Paco

AU - Janssen, Nard

AU - Rosenberg, Toine

AU - Pandit, Aridaman

AU - Tao, Weiyang

AU - Hillen, Maarten

AU - Kruize, Aike A.

AU - Radstake, Timothy R.

PY - 2019/6

Y1 - 2019/6

U2 - 10.1136/annrheumdis-2019-eular.5681

DO - 10.1136/annrheumdis-2019-eular.5681

M3 - Meeting Abstract

SN - 0003-4967

VL - 78

SP - 396

EP - 396

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl 2

ER -